Mains Ready By December. Smash Mains & Smash PYQ Admissions Open
Talk to Mentor

Civilsdaily

GS Paper: GS3-17.Awareness in the fields of IT, Space, Computers, Robotics, Nano-technology, Bio-technology and issues relating to Intellectual Property Rights.

  • Why Weekly Diabetes Shot Could Reshape Treatment

    Why in the News?

    Novo Nordisk launched Awiqli (insulin icodec), the world’s first once-a-week insulin injection, in India, cutting required insulin shots from 365 to 52 a year at Rs 261 per week. The launch targets India’s exceptionally large and growing diabetic population, but insulin use in India has long lagged clinical need because of reluctance among both patients and doctors to initiate insulin therapy.

    How does icodec technically reduce insulin’s dosing burden without changing its clinical effect?

    1. Albumin-binding depot: A fatty acid chain added to the insulin molecule increases its affinity for albumin, a blood protein. Delivered under the skin, the drug binds reversibly to albumin, forming an inactive depot that releases insulin into the bloodstream through the week.
    2. Reduced receptor affinity: Three amino acid substitutions lower the molecule’s affinity for insulin receptors. This slows the rate at which released insulin is used up, without reducing its potency.
    3. Injection frequency reduction: The two modifications together cut insulin injections from 365 days a year to 52 days, making icodec the world’s first long-acting weekly insulin shot.
    4. Clinical equivalence, not clinical superiority: Physicians state icodec’s blood sugar-lowering effect is similar to other insulins. The advance lies in reduced dosing frequency, expected to improve compliance rather than glucose control itself.
    5. Position in insulin’s evolution: Icodec is a genetically engineered insulin analogue (Insulin analogue: a modified version of human insulin engineered to alter how long it stays active or how it is absorbed), part of a line of modifications that extend how long insulin stays active in the body.

    Why does India’s insulin gap persist despite insulin’s proven superiority over oral therapy?

    1. Patient reluctance despite clinical failure of pills: Type 2 diabetics who have failed to control blood glucose even on the highest doses of oral medicines remain unwilling to switch to insulin shots, despite the risk of organ, nerve, and eye damage from delay.
    2. Physician-side reluctance: Doctors themselves show reluctance to initiate insulin treatment in patients, delaying transition even when maximal oral therapy has failed.
    3. Insulin’s undeserved stigma: Novo Nordisk India’s managing director states insulin is a drug that is never abused and is highly effective, yet patients avoid it, indicating the barrier is perceptual rather than clinical.
    4. Scale of underuse: Only six million people are currently on insulin in India, a number industry estimates should be at least double, given the population that clinically needs it.
    5. Gendered burden compounding avoidance: Women on multiple daily insulin doses report needing to adjust doses during menstruation, a flexibility burden not addressed by frequency reduction alone.

    Which patient groups does icodec target, and why does the clinical logic differ between type 1 and type 2 diabetes?

    1. First target group: treatment-failed type 2 diabetics: Patients with eight to ten years of diabetes whose pills can no longer control blood glucose are the primary intended users, to prevent further organ and nerve damage from delay.
    2. Second target group: background insulin for type 1 diabetics: Type 1 diabetics need a long-acting basal dose (Basal dose: a steady, long-acting insulin dose that manages blood glucose between meals) alongside meal-time bolus doses (Bolus dose: a fast-acting insulin dose taken around mealtimes based on calorie intake); icodec would add a fourth weekly dose without significantly raising treatment burden.
    3. Why type 2 is the better clinical fit: Type 1 diabetics already take three daily doses, and their blood glucose fluctuates more, requiring frequent dose adjustment that weekly dosing cannot accommodate.
    4. Loss of flexibility as a trade-off: A physician-run survey found women needed to adjust insulin doses during menstruation, a flexibility that a fixed weekly dose foreclosed for type 1 patients.
    5. Type 2’s larger untapped pool: Since 25% to 30% of type 2 diabetics eventually require insulin despite most managing initially on pills, this is the segment with the largest late-stage conversion potential.

    Does icodec’s safety and cost profile remove the practical objections to insulin therapy?

    1. Hypoglycemia risk unchanged: The most common side effect, hypoglycemia (Hypoglycemia: a condition where blood glucose levels fall too low), affects about one in ten people on icodec, matching the risk seen with other daily insulin shots.
    2. Why hypoglycemia appears more noticeable on insulin: Blood glucose is controlled for the first time once insulin is started, making hypoglycemic episodes more apparent; pills can cause hypoglycaemia too, but uncontrolled high glucose on pills masks the comparison.
    3. Weekly cost undercuts existing insulin analogues: Icodec costs Rs 261 a week, compared to Rs 345 to Rs 453 a week for existing insulin analogues, working out to about Rs 50 a day.
    4. Pricing structure: The drug is sold in two pre-filled pen sizes, a 700 ml unit priced at Rs 2,611 and a 2,100 ml unit priced at Rs 7,883, with a typical patient needing around 70 units a week depending on requirement.
    5. Combination potential with weight-loss drugs: Icodec becomes more effective when combined with GLP-1 drugs (GLP-1 drugs: a class of medicines that lower blood glucose and are also used for weight loss), since abdominal obesity reduces insulin sensitivity and raises the insulin needed to process the same amount of sugar.

    Does convenience alone close India’s insulin treatment gap?

    1. Scale of the underlying burden: India currently has 101 million people living with diabetes and 136 million with pre-diabetes, one of the largest such populations in the world.
    2. Projected insulin need over time: Industry estimates suggest 5% to 10% of diabetics would need insulin after five years of pill-based management, rising to 20% to 30% after ten years.
    3. Conservative estimate still implies a large gap: Even at a conservative 20% requirement, the number needing insulin would stand at around 20 million, more than three times the current six million on insulin.
    4. Convenience as the stated lever for closing this gap: Industry framing ties the drug’s adoption prospects explicitly to convenience and comparable cost, not to any claimed improvement in glucose control.
    5. Unaddressed question: Whether reduced dosing frequency by itself overcomes the reluctance documented among both patients and doctors, distinct from cost or frequency, is not established by the launch itself.

    Conclusion

    Icodec’s weekly dosing and competitive pricing directly target the practical barriers of frequency and cost that have long deterred insulin use in India. The deeper barrier is behavioural: both patients and physicians delay insulin initiation despite its established superiority over maximal oral therapy, driven by stigma and reluctance rather than price or frequency alone. Reducing shots from 365 to 52 a year does not by itself address this psychological resistance. Whether convenience translates into earlier insulin initiation, and closes the gap between India’s 101 million diabetics and the roughly 20 million projected to eventually need insulin, will depend on physician-driven behavioural change as much as on the drug’s technical advance.

  • NeoSep1 Trial to Combat Antimicrobial Resistant Neonatal Sepsis

    Why in News?

    India has joined the NeoSep1 international trial to evaluate effective antibiotic combinations for treating antimicrobial resistant (AMR) neonatal sepsis.

    Key Highlights

    • NeoSep1 is a multicentric clinical trial led by GARDP and international partners.
    • India’s first participants were enrolled at:
      • JIPMER, Puducherry
      • PGIMS, Rohtak
    • The trial aims to enrol 3,000 newborns across Asia and Africa by 2028.
    • Uses a Personalised Randomised Controlled Trial (PRACTical) design to identify the most effective antibiotic regimens.
    • Primary outcome: 28 day survival; secondary outcomes include 90 day survival, hospital stay, and need for additional antibiotics.

    Neonatal Sepsis

    • A life threatening bloodstream infection in infants below 90 days of age.
    • Classified as:
      • Early onset: Within 72 hours of birth.
      • Late onset: Up to 28 to 90 days after birth.
    • Premature and low birth weight babies are at the highest risk.

    India and AMR

    • Accounts for 30 to 40% of neonatal deaths in India.
    • Causes an estimated 2 to 2.5 lakh preventable deaths annually.
    • Predominant pathogens: Klebsiella pneumoniae. Escherichia coli. Acinetobacter spp. Pseudomonas aeruginosa
    • These organisms often exhibit multidrug resistance, unlike developed countries where Group B Streptococcus is the leading cause.

    [2019] Which of the following are the reasons for the occurrence of multi-drug resistance in microbial pathogens in India?
    1. Genetic predisposition of some people
    2. Taking incorrect doses of antibiotics to cure diseases
    3. Using antibiotics in livestock farming
    4. Multiple chronic diseases in some people
    Select the correct answer using the code given below.

    [A] 1 and 2

    [B] 2 and 3 only

    [C] 1, 3 and 4

    [D] 2, 3 and 4

  • China Achieves First Controlled Recovery of Reusable Rocket Booster

    Why in News?

    China has successfully conducted its first controlled recovery of an orbital class reusable rocket booster during the maiden launch of the Long March 10B carrier rocket, marking a significant milestone in its reusable space technology.

    Key Highlights

    • Long March 10B successfully placed its payload into the designated orbit.
    • After stage separation, the first stage booster returned safely and was captured on a sea based platform using a net capture system.
    • This marks China’s first successful controlled recovery of an orbital class rocket booster.
    • The achievement follows SpaceX, which became the first to recover an orbital class rocket booster in December 2015.
    • Two previous Chinese attempts at vertical landing in December 2025 had failed.

    What is a Reusable Launch Vehicle (RLV)?

    • A launch vehicle designed to recover and reuse some or all of its components after launch.
    • Typically, the first stage booster is recovered since it accounts for a major share of launch costs.
    • Recovery methods include:
      • Vertical landing on land or drone ships (SpaceX).
      • Sea based platform recovery using net capture (Long March 10B).
    • Reusability significantly lowers the cost of access to space.

    Benefits of Reusable Rocket Technology

    • Reduces launch costs through multiple reuse of boosters.
    • Enables higher launch frequency.
    • Improves commercial viability of space missions.
    • Supports deep space exploration and satellite deployment.
    • Reduces manufacturing time and resource consumption.

    China’s Long March Rocket Family

    • Developed by the China Academy of Launch Vehicle Technology (CALT).
    • Serves as China’s primary family of orbital launch vehicles.
    • Used for: Satellite launches. Human spaceflight missions. Lunar and deep space exploration.
    • Long March 10 is being developed for China’s future crewed Moon missions.

    India’s Reusable Launch Vehicle (RLV) Programme

    • Developed by ISRO.
    • Aims to create a fully reusable space transportation system.
    • Key milestones:
      • RLV-TD (Reusable Launch Vehicle Technology Demonstrator) first flew in 2016.
      • LEX (Landing Experiment) successfully demonstrated autonomous runway landing in 2023.
      • LEX-02 and LEX-03 further validated autonomous landing technologies.
    • Intended to reduce launch costs and improve access to space.

    [2018] With reference to India’s satellite launch vehicles, consider the following statements :
    1.PSLVs launch satellites useful for Earth resources monitoring whereas GSLVs are designed mainly to launch communication satellites.
    2.Satellites launched by PSLV appear to remain permanently fixed in the same position in the sky, as viewed from a particular location on Earth.
    3.GSLV Mk III is a four-stage launch vehicle with the first and third stages using solid rocket motors, and the second and fourth stages using liquid rocket engines.
    Which of the statements given above is/are correct?

    [A] 1 only

    [B] 2 and 3

    [C] 1 and 2

    [D] 3 only

  • Mission Drishti Loses Communication After Solar Storm

    Why in News?

    Mission Drishti, developed by Bengaluru based GalaxEye, lost communication after a geomagnetic solar storm affected the satellite during the Launch and Early Orbit Phase (LEOP).

    Key Highlights

    • Launched on 3 May 2026 aboard SpaceX Falcon 9 from Vandenberg, California.
    • World’s first OptoSAR satellite, combining optical imaging and Synthetic Aperture Radar (SAR).
    • India’s largest privately developed Earth observation satellite.
    • Radiation from the solar storm likely affected a critical onboard system, causing communication loss.
    • Recovery efforts are ongoing, but chances of recovery are currently low.

    What is OptoSAR?

    • Integrates optical cameras with Synthetic Aperture Radar (SAR).
    • Provides high-resolution imaging in all weather conditions, including through clouds and at night.
    • Useful for disaster management, agriculture, defence, mapping, and environmental monitoring.

    Significance

    • Validated several indigenous satellite technologies and mission operations.
    • Strengthens India’s private space ecosystem.
    • Lessons from the mission will improve future spacecraft reliability.
    • GalaxEye plans to launch two next-generation OptoSAR satellites within the next 24 months.

    [2022] If a major solar storm (solar flare) reaches the Earth, which of the following are the possible effects on the Earth?:
    1. GPS and navigation systems could fail.
    2. Tsunamis could occur at equatorial regions.
    3. Power grids could be damaged.
    4. Intense auroras could occur over much of the Earth.
    5. Forest fires could take place over much of the planet.
    6. Orbits of the satellites could be disturbed
    7. Shortwave radio communication of the aircraft flying over polar regions could be interrupted.
    Select the correct answer using the code given below;

    [A] 1, 2, 4 and 5 only

    [B] 2, 3, 5, 6 and 7 only

    [C] 1, 3, 4, 6 and 7 only

    [D] 1, 2, 3, 4, 5, 6 and

  • Oldest Quasars Ever Discovered by Euclid Telescope

    Why in News?

    The European Space Agency’s (ESA) Euclid Space Telescope has discovered 31 ancient quasars, including the oldest ever observed, dating back to when the Universe was about 670 million years old.

    Key Highlights

    • Quasars are the extremely bright cores of distant galaxies powered by supermassive black holes.
    • The newly discovered quasars belong to the Epoch of Reionisation, when the first stars and galaxies formed.
    • Euclid has doubled the number of known ancient quasars within two years.
    • The findings deepen the mystery of how supermassive black holes grew to billions of solar masses so soon after the Big Bang.
    • The James Webb Space Telescope (JWST) will further study these quasars to understand the early Universe.

    Significance

    • Helps trace the reionisation of the Universe.
    • Improves understanding of the formation of early galaxies and black holes.
    • Challenges existing models of cosmic evolution.

    UPSC Prelims Value Addition

    • Quasar: The highly luminous active galactic nucleus (AGN) of a distant galaxy, powered by matter falling into a supermassive black hole.
    • Epoch of Reionisation: The period (about 400 million to 1 billion years after the Big Bang) when the first stars and galaxies ionised neutral hydrogen, ending the Cosmic Dark Ages.

    [2017] The terms ‘Event Horizon’, ‘Singularity’, ‘String Theory’ and ‘Standard Model’ are sometimes seen in the news in the context of:

    (a) Observation and understanding of the Universe

    (b) Study of the solar and the lunar eclipses

    (c) Placing satellites in the orbit of the Earth

    (d) Origin and evolution of living organisms on the Earth

  • AI is rehsaping warfare: How can India keep pace

    Why in the News?

    Recent operations in Ukraine, Venezuela and Iran show AI-fused targeting, autonomous drone swarms and machine-speed strikes compressing engagement timelines and deciding outcomes. This convergence is shifting the basis of military power from hardware inventory to software velocity, exposing India’s defence establishment as structurally unprepared for the shift from a weapons-manufacturing model to a software-enterprise model.

    Why is algorithmic precision replacing hardware mass as the decisive factor in war?

    1. Simultaneous convergence: AI, autonomy and algorithmic precision are advancing together, not in sequence. Their combined effect multiplies battlefield lethality rather than adding to it.
    2. Historic scale of disruption: The deployment of software at unprecedented speed and scale in combat is being compared to a Manhattan Project moment. It marks a comparable inflection point to the arrival of gunpowder and nuclear weapons.
    3. Inverted innovation cycle: Software in combat theatres is updated every three weeks. New hardware is fielded only every three months. The traditional hardware-leads-software model has reversed.
    4. Institutional identity under strain: The Ministry of Defence has functioned as a platform and weapons factory. This shift requires it to function as a software enterprise instead.

    What do recent conflicts and defence-tech ventures reveal about AI-driven warfare?

    1. Ukraine (Delta platform): Delta fuses radar imagery, satellite feeds and social media data into one stream. It links to a drone inventory to form a “kill web” that compresses detection-to-neutralisation time to a couple of minutes.
    2. Ukraine (drone battlefield economy): Ukraine is procuring eight million drones this year, more than the artillery shells it fired last year. These platforms range from 25 km tactical close air support to 2,500 km strategic strike.
    3. Venezuela (US use of Anthropic’s Claude): American forces used the commercial AI model Claude to track the movements of ousted president Nicolás Maduro. This intelligence was synchronised with electronic attacks, cyber exploits and a Delta Force heliborne assault to capture him.
    4. Iran (machine-speed targeting): Targeting packages generated at machine, not human, speed enabled strikes that eliminated almost the entire Iranian military leadership within minutes on a single morning.
    5. United States (Anduril’s YFQ-44A Fury): A defence-tech startup, not a legacy defence prime, built this AI-powered unmanned fighter jet. It is designed to operate independently or team with crewed aircraft, showing that defence innovation is migrating toward agile startups.

    What competitive and structural pressures complicate India’s adaptation to this shift?

    1. Chinese software threat: A tool named Mythos functions as a virtual cyber-nuke capable of disabling an adversary’s operating system. This shows offensive capability has moved beyond kinetic weapons into software itself.
    2. Chinese hardware race: Huawei is pursuing 1.4 nanometre transistor density by 2031 to challenge Nvidia’s 4 nanometre Blackwell chips. This targets the compute layer that underpins AI-driven weapons systems.
    3. Speed as a structural constraint: A three-week software cycle against a three-month hardware cycle cannot be matched by an organisation built around multi-year procurement timelines.
    4. Institutional inertia as the central obstacle: The Ministry of Defence’s identity as a weapons and platform manufacturer conflicts directly with the software-enterprise model this warfare paradigm demands. Resolving this conflict is the precondition for everything else.

    What sovereign pathways can India adopt to close this gap?

    1. Sovereign data fusion: India must urgently build its own AI-enabled data analytics platform in the manner of Delta, rather than depend on external systems.
    2. Autonomous coordination software: Software must independently coordinate drone swarms, identify objects of interest, distinguish civilian aircraft and birds from combat platforms, and direct shooters to destroy targets.
    3. Drone inventory at scale: India should build a diverse drone inventory with a target of five million units by 2028.
    4. Counter-drone kill webs: Laser and microwave counter-drone systems paired with drone-hunting teams should establish AI-enabled kill webs along the LoC and LAC.
    5. Space-based ISR: India should crowd low-earth orbit space to transition from persistent surveillance to offensive intelligence, surveillance and reconnaissance.
    6. Budget reallocation: At least 40% of the roughly Rs 2 lakh crore modernisation budget for 2027 should go to technological solutions rather than conventional hardware.

    Conclusion

    The decisive factor in modern warfare is shifting from hardware inventory to algorithmic velocity. Whoever controls faster AI-driven sense-decide-strike cycles gains advantage regardless of platform numbers. India cannot depend on borrowed or externally controlled AI and autonomy systems in a live conflict; it must build sovereign capability across data platforms, autonomous software, drone and counter-drone infrastructure, and space-based ISR. This requires the Ministry of Defence to transform from a weapons-manufacturing body into a software enterprise, a cultural and structural shift whose outcome remains untested.

    PYQ Relevance

    [UPSC 2023] Introduce the concept of Artificial Intelligence (AI). How does AI help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?

    Linkage: The PYQ examines the transformative applications of Artificial Intelligence (AI), its strategic implications, and the challenges arising from its deployment. The article extends AI’s application from the civilian domain to warfare, highlighting how AI-enabled autonomous systems, algorithmic warfare, and human-machine teaming are redefining military strategy, deterrence, and national security.

  • Gaganyaan: ISRO Conducts First SOLVE Ground Test

    Why in News?

    ISRO successfully conducted the first ground test of the Sub-Orbital Launch Vehicle for Experiments (SOLVE) solid motor at the Satish Dhawan Space Centre, Sriharikota, for the Gaganyaan Mission.

    What is SOLVE?

    • SOLVE (Sub-Orbital Launch Vehicle for Experiments) is a solid motor-based test vehicle developed by ISRO.
    • It is designed to validate the Crew Module’s parachute-based deceleration system under different mission conditions.
    • A key component for future Gaganyaan Test Missions.

    Key Features

    • Carries the Crew Module to an altitude of 10 to 17 km.
    • After separation, a series of 10 parachutes slows the Crew Module before sea splashdown.
    • Solid motor derived from the PSLV Strap-on Motor with modifications such as:
      • Slow burn-rate propellant.
      • Straight nozzle with Secondary Injection Thrust Vector Control (SITVC).

    Significance

    • Validates the Crew Module recovery system.
    • Provides flexibility to simulate different mission scenarios.
    • Supports upcoming uncrewed and crewed Gaganyaan missions.

    About Gaganyaan Mission

    • India’s first human spaceflight mission.
    • Objective: Demonstrate the capability to send three astronauts to a 400 km Low Earth Orbit (LEO) for about three days and safely recover them in Indian waters.
    • Implemented by ISRO.

    [2025] Consider the following space missions:
    I. Axiom-4
    II. SpaDeX
    III. Gaganyaan
    How many of the space missions given above encourage and support microgravity research?

    [A] Only one

    [B] Only two

    [C] All the three

    [D] None

  • Antibiotics to creams: The perils of combination meds

    Why in the News?

    The government has banned 16 fixed-dose combination (FDC) drugs, including antibiotic and dermatological formulations, for lacking scientific justification. The ban exposes that many combinations survived in the market for years on commercial convenience rather than clinical evidence. This exposed patients to unnecessary risk and worsening antimicrobial resistance.

    What triggered the ban on 16 fixed-dose combination drugs?

    1. Scope of the ban: The government banned 16 FDC drugs, covering antibiotic combinations and dermatological products containing aloe vera and other herbal ingredients.
    2. Stated ground for the ban: The banned products lack scientific justification for their claimed amplified benefit.
    3. Definition of the underlying problem: An FDC is irrational when its ingredients have no scientifically established rationale for being combined in a single product.
    4. Test for rationality: Each component must contribute meaningfully to the intended therapeutic effect, have compatible pharmacological properties, and demonstrate additional clinical benefit compared to using the medicines individually.
    5. Evidentiary gap: In many banned cases, no clinical trial evidence supports the combination.

    Why does a combination drug’s long presence in the market not establish its scientific validity?

    1. Central tension: Longevity in the market does not establish scientific validity.
    2. Case in point: Many banned dermatological combinations contained aloe vera extracts, vitamin E, jojoba oil, olive oil, tea tree oil, and other moisturising or herbal components, sold for years despite lacking evidence.
    3. The real question: Whether combining these ingredients produces a measurable clinical benefit compared with using them individually.
    4. Evidentiary standard: Robust scientific evidence demonstrating superior efficacy is lacking for many such products.
    5. Illustrative failure: Combination creams pairing a steroid and an antifungal give temporary relief from itching and redness because the steroid suppresses the skin’s local immune response, but this same suppression allows the underlying fungal infection to worsen, spread, or become resistant to treatment.
    6. Governance root cause: In the pre-reform period, thousands of FDCs were approved by state licensing authorities without central review, exploiting a regulatory loophole in the Drugs & Cosmetics Act. 

    What do specific banned combinations reveal about irrational drug design?

    1. Amoxicillin + serratiopeptidase: Serratiopeptidase is acid-labile, meaning it degrades in the stomach before reaching the bloodstream.
    2. No demonstrated benefit: No evidence shows that adequate therapeutic concentrations of serratiopeptidase reach infected tissues.
    3. No trial support: No peer-reviewed randomised controlled trial has shown that adding serratiopeptidase improves bacterial clearance, increases cure rates, or reduces the antibiotic dose required.
    4. Norflox TZ (norfloxacin + tinidazole): Tinidazole is pointless for purely bacterial diarrhoea; norfloxacin provides zero benefit for amoebic dysentery. Patients rarely have both infections simultaneously, yet exposure to both drugs unnecessarily promotes bacterial resistance.
    5. Augmentin 625 (amoxicillin + clavulanic acid): Clavulanic acid blocks the enzyme that resistant bacteria use to destroy amoxicillin, but is useless if the infecting bacteria are not resistant.
    6. Guideline recognition: No major treatment guideline currently recommends serratiopeptidase as an antibiotic adjunct for managing infections.

    What does global regulatory practice show about evaluating combination drugs?

    1. United States: All FDCs require a new drug application supported by clinical evidence of superiority or convenience over the individual components.
    2. World Health Organization: The WHO explicitly cautions against irrational FDCs; only combinations on its essential medicines list are treated as evidence-based.
    3. European Union: FDCs undergo full scientific review and can be justified only with supporting clinical data.
    4. India (pre-reform): Thousands of FDCs were approved by state licensing authorities without central review, exploiting a loophole in the Drugs & Cosmetics Act.
    5. India (post-2016): Around 6,000 FDCs were reviewed by a central committee, and bans have been initiated in phases since.

    How do irrational antibiotic combinations contribute to antimicrobial resistance?

    1. Marketing effect: When combinations are marketed as more effective without sufficient evidence, they encourage unnecessary and prolonged antibiotic use.
    2. Exposure pathway: This increases antibiotic exposure in the community and creates selective pressure on bacteria.
    3. Resistance mechanism: Selective pressure allows resistant organisms to survive and multiply.
    4. Policy implication: From a public health perspective, antibiotic use should be as targeted and evidence-based as possible.
    5. Scale of the underlying problem: AMR is a growing public health problem because bacteria, viruses, fungi, and parasites no longer respond to the medicines designed to kill them.

    What risks do patients face from irrational FDCs?

    1. Unnecessary drug exposure: Patients face an increased possibility of adverse effects, drug interactions, and allergic reactions.
    2. Dose inflexibility: Fixed combinations make it difficult for doctors to adjust the dose of individual ingredients to a patient’s needs.
    3. Titration failure: If a doctor wants to increase the dose of one medication, this cannot be done without also increasing the other.
    4. Diagnostic masking: Combination drugs can mask an underlying complication, reducing precision in treatment.

    What should patients, doctors, and pharmacists do now that these products are banned?

    1. Patient understanding: A medicine with multiple ingredients is not necessarily more effective than a targeted treatment.
    2. Preferred alternative: A simpler medicine supported by strong evidence is often the safer and more effective option.
    3. Continuity of care: Patients using banned products should consult their doctor about alternatives; stopping an irrational FDC does not mean stopping treatment.
    4. Doctor’s role: The focus should be on de-escalating patients to rational therapies supported by evidence.
    5. Pharmacist’s role: Pharmacists should track the regulator’s list of banned FDCs, flag irrational prescriptions, and educate patients on available alternatives.
    6. Related caution- vitamins and probiotics with antibiotics: There is no definitive evidence that pairing them with antibiotics is indispensable; probiotics may be advised case-by-case, and vitamins are generally unnecessary for a short antibiotic course except in vulnerable groups.

    Conclusion

    A drug combination’s survival in the market does not establish its scientific validity; irrational FDCs persisted because regulatory review was historically weak, not because evidence supported them. Regulatory decisions on combination drugs must rest on clinical trial evidence and risk-benefit assessment rather than duration of commercial availability. Continuous post-marketing surveillance is needed to identify and withdraw irrational combinations before they further entrench antimicrobial resistance.

    PYQ Relevance

    [UPSC 2013] What do you understand by Fixed Dose Drug Combinations (FDCs)? Discuss their merits and demerits.

    Linkage: The PYQ asks for a direct conceptual and evaluative treatment of FDCs. The article supplies current, case-specific demerits (Norflox TZ, Augmentin 625, serratiopeptidase, dermatological creams) that can update and substantiate this answer.

  • [1st July 2026] The Hindu OpED: Reimagining sovereign AI for India’s strategic future 

    Mentor’s Comment

    The United States government directed Anthropic to suspend foreign national access to its Fable 5 and Mythos 5 AI models on national security grounds, and is separately considering equity stakes in leading AI companies. At the same time, India lacks frontier AI capability of its own and must rely on foreign models to remain competitive. This dependence carries geopolitical risk that neither market competition nor inter-ministerial coordination alone can resolve.

    What explains the global turn toward sovereign AI policymaking, and why does India need a coordinated response?

    1. US export controls: The US suspended foreign national access to Anthropic’s Fable 5 and Mythos 5 models on national security grounds and created a voluntary mechanism for federal government access up to 30 days before trusted partners.
    2. Equity stake consideration: The US administration is considering taking equity stakes in leading AI firms to capture a share of the supernormal profits expected from the technology.
    3. Global pattern: Governments are increasingly shaping AI policy around national advantage rather than leaving diffusion purely to markets.
    4. India’s structural gap: India is a large IT services economy without its own frontier AI systems (Frontier AI: AI systems requiring upwards of ten septillion floating-point operations to train).
    5. Reason for urgency: Policy decisions made elsewhere increasingly determine the terms on which India can access frontier technology, making a coherent domestic response necessary now.

    Why is India’s AI policy discourse trapped in a false binary, and why must this framing be rejected?

    1. The dependence dilemma: India’s IT and app companies must use the best available foreign AI to remain competitive, yet this use deepens dependence on models built abroad.
    2. Sequencing logic: Using foreign AI today builds the economic surplus needed to depend on it less in future. Diffusion and dependence-reduction are sequential goals, not opposed ones.
    3. Limits of firm-level action: Firms can outcompete rivals using foreign AI. Firms cannot manage the geopolitical risks that accompany dependence on it. That risk-management role falls to public policy.
    4. False binary named: India’s discourse frames globalisation and industrial policy as mutually exclusive. Indian industry must benefit from both at the same time.
    5. Pharma precedent: Indian pharmaceutical manufacturing shows the limits of industrial policy alone. A Production-Linked Incentive (PLI: a government scheme offering incentives tied to incremental domestic manufacturing output) promoted domestic bulk drug production. India still sources 65% of critical ingredients from China, per NITI Aayog’s latest assessment.
    6. Implication: Industrial policy creates footholds. It does not create instant resilience. This sets the correct expectation for AI policy as well.

    What institutional architecture should India build to benefit from frontier AI without deepening strategic dependence?

    1. Scale of the gap: India spends 0.6% of GDP on research and development, of which the private sector accounts for a third. OpenAI alone projects $50 billion in compute spending this year, over six times India’s annual private R&D spend.
    2. Strategic implication: India cannot outspend frontier AI investment. India must instead deepen backward linkages to frontier AI while strengthening forward linkages for its own products and services.
    3. Whole-of-government approach: Ministries of external affairs, commerce, and information technology must coordinate closely. Coordination should extend to defence, energy, and telecom where relevant.
    4. Objective of coordination: The architecture secures continued access to frontier AI inputs. It simultaneously builds global market access for Indian AI-enabled products and services.

    Since coordination alone cannot manage geopolitical risk, what role must the state play in underwriting it?

    1. Limits of firm-level risk management: Firms can manage commercial risk through contracts and diversified supply chains. Firms cannot insure themselves against geopolitical risk or concentrated technological dependence.
    2. Sovereign risk-bearing role: Underwriting such risk is a function only the state can perform. Private capital cannot efficiently bear this risk alone.
    3. Export credit analogy: Export credit mechanisms insure firms against risks they cannot shoulder independently in international trade, offering a template for AI-related risk underwriting.
    4. Hybrid-annuity analogy: The Hybrid-Annuity Model (HAM: an infrastructure financing structure where the state funds part of a project and makes fixed payments over time) reduces the share of risk borne by private capital in long-gestation infrastructure. A comparable approach could apply to frontier AI dependence.

    What do the available global examples suggest about alternative sovereign AI strategies? 

    1. Europe: Shifted from a “regulate first, ask questions later” approach to investing directly in AI compute capacity and promoting “Buy European” public procurement to support its domestic AI industry.
    2. Argentina: Is positioning itself to attract AI investment by offering a regulatory safe harbour under an accommodative regulatory posture.

    Why must India’s technology industry itself close the competitiveness gap, and what does this reveal about the limits of policy alone?

    1. Government’s limits: Government action can create conditions for success. Competitiveness must ultimately come from firms themselves.
    2. Export benchmark: The Philippines generates $40 billion in IT exports, nearly a sixth of India’s IT exports, and is growing faster than the global industry.
    3. App market underperformance: No Indian app features among the top 10 globally by downloads, in-app purchase revenue, or monthly active users.
    4. Fragmented industry voice: Incumbent IT firms remain focused on visas and market access. Startups remain consumed by regulatory friction and fundraising. Both share a common interest in India’s continued connection to global AI ecosystems alongside growing domestic capability.
    5. Core stakes: The central contest in AI is not only over who builds the best models. It is over who captures the economic and strategic advantages the models create.

    Conclusion

    India’s AI strategy must reject the false choice between global integration and domestic capability building. The objective is to remain deeply integrated with global AI ecosystems while steadily reducing the strategic vulnerabilities such integration creates. This requires backward linkages secured through whole-of-government coordination, forward linkages built through competitive Indian products and services, and state-backed risk underwriting on the export-credit and hybrid-annuity model. Without matching ambition from industry itself, government action alone cannot close the gap.

  • [30th June 2026] The Hindu OpED: Why artificial wisdom is the biggest AI risk

    PYQ Relevance[UPSC 2023] Introduce the concept of Artificial Intelligence (AI). How does AI help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?
    Linkage: The PYQ tests understanding of AI’s applications alongside ethical concerns such as privacy, accountability and responsible deployment. The article extends the debate beyond privacy to examine AI-generated misinformation, concentration of AI power, the limits of machine-generated knowledge, and the need for robust AI governance and regulation.

    Mentor’s Comment

    AI debates have centred on job losses and concentration of power among a few firms and nations. A third, less discussed risk is emerging: AI is being treated as a substitute for human cognition, even though it produces information, not knowledge. The conflation of AI output with genuine knowledge has no such precedent and currently has no accountability structure attached to it.

    Why are labour displacement and power concentration considered the more manageable AI risks?

    1. Historical precedent on labour: Technology has automated specific tasks, not entire professions; the steam engine displaced labour into new industries rather than eliminating it.
    2. Expected AI trajectory: Some occupations will shrink, others will expand, and new professions will emerge, mirroring past transitions.
    3. Transition cost is real: The shift will require substantial investment in reskilling, but is not existential.
    4. Capital-intensive economics of AI: Frontier models require massive investment in computing infrastructure, energy, talent and data, restricting ownership to a few firms and countries.
    5. Concentration risk has known parallels: Concentrated control of strategic resources such as gold or oil has historically produced geopolitical leverage and coercive behaviour.
    6. Institutional tools already exist: Legal institutions, international treaties and negotiated frameworks have managed comparable concentration risks before.

    What is the curse of “artificial wisdom” and why is it the most dangerous AI risk?

    1. Core misconception: AI enthusiasts position AI as a substitute for human cognition, leading society to internalise the belief that AI generates knowledge.
    2. What AI actually does: An AI system is trained on data to learn patterns and statistical relationships, and predicts the most probable next step in a sequence.
    3. Knowledge versus information: Information is what AI produces; Knowledge: understanding that requires context, judgment, experience and an understanding of consequences.
    4. Verification requires expertise: Only a human mind with domain expertise can judge whether AI-generated output is useful and appropriate for a given problem.
    5. Why this risk is least understood: It is structurally different from labour and power risks because it changes how truth itself is assessed, not just who holds resources or jobs.

    How does the information-knowledge conflation translate into systemic harm?

    1. Synthetic information advantage: AI-generated content can be more persuasive, accessible or appealing than genuine information.
    2. Erosion of fact-fabrication distinction: Individuals and institutions struggle to separate fact from fabrication, creating conditions for manipulation and misinformation.
    3. Organisational dependence: Organisations increasingly use AI for research, coding, legal drafting and financial analysis.
    4. Unverifiable decision-making: This creates systemic risk because decisions are influenced by intelligence that nobody is qualified to verify.
    5. Paradox of expertise: The AI age makes genuine domain expertise more valuable, since the rarest skill becomes determining whether machine-generated answers are correct.

    Why does AI’s accountability gap require a new governance architecture?

    1. Existing liability model: Manufacturers of harmful pharmaceutical products can be held accountable under established liability law.
    2. AI’s liability gap: AI systems have largely operated without comparable clear liability.
    3. Emerging accountability signal: Meta Platforms has faced lawsuits alleging that its platform design contributed to harm among young users, indicating accountability boundaries are beginning to be redrawn for digital platforms.
    4. Proposed safeguard structure: The response requires both technical and institutional safeguards, backed by a global non-proliferation agreement on disruptive AI.
    5. Containment objective: Such an agreement must allow humans to limit or shut down AI systems operating outside their intended boundaries.
    6. Precedent for restraint: Humanity has avoided nuclear catastrophe for eight decades; AI governance is framed as a comparable challenge of sustained, deliberate restraint.

    Conclusion

    The defining AI risk is not job loss or concentrated ownership, both of which have historical management precedents. It is the unchecked substitution of AI-generated information for genuine knowledge, compounded by the absence of liability and verification structures. Closing this gap requires a global governance architecture combining technical safeguards, institutional accountability, and a non-proliferation framework for disruptive AI capabilities, built before reliance on unverified AI output becomes irreversible.